分幅摄像机构

本发明涉及高速摄影技术，具体的说是涉及一种分幅摄像机构，主要解决了现有分幅摄像机构不易密封，加工难度大的问题。该分幅摄像机构包括依次电连接的分幅相管、CCD、电源与控制机构、传感机构，和圆柱形机构，圆柱形机构包括支架和柱形套筒，柱形套筒的内径与支架的外径相适配，柱形套筒套接在支架上；分幅相机、CCD、电源与控制机构和传感机构设置于圆柱形机构的支架内。本发明提供的分幅摄像机构密封长度小，易于实现真空密封，漏率小，所有内部单元固定在其上形成整体，方便装入

基于半导体激光器的脉冲整形技术

论述一种新的激光脉冲整形方法-利用任意形状的整形电脉冲直接驱动半导体激光器,产生与电脉冲形状一致的激光脉冲,作为高功率激光装置的种子光源。使用GaAs场效应管作为开关器件,使用超宽带脉冲触发场效应管产生整形电脉冲,引入阻抗渐变微带技术克服了触发脉冲损耗对级联场效应管数量限制,将整形电脉冲脉冲宽度扩展到10 ns。以整形电脉冲直接驱动半导体激光器,可产生脉宽为10 ns,时域调节精度为330 ps的任意整形激光脉冲

中国鼠疫自然疫源地分型研究Ⅶ.中国鼠疫自然疫源地分型生物学特征/Ecological-geographic landscapes of natural plague foci in China Ⅶ.Typing of natural plague foci[J]

目的 研究中国鼠疫自然疫源地分型.方法 根据中国鼠疫自然疫源地鼠疫生态地理景观学、鼠疫耶尔森菌基因组学、鼠疫宿主动物学、鼠疫媒介昆虫学特征,提出“鼠疫生物地理群落指征、两级分型法和三项指征命名法”；区划中国鼠疫自然疫源地型及其亚型.结果 中国鼠疫自然疫源地分为12型19亚型.阐明中国鼠疫自然疫源地生物学特征.结论 中国鼠疫自然疫源地型及其亚型的划分,为掌握其生物学基本规律奠定基础

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials